Amgen Kicks Off Pembrolizumab Program As It Delivers Q1 Results

ABP234 Proposed Keytruda Rival Is Latest Asset For Amgen’s Biosimilars Business

 
• By David Wallace
  
Amgen logo next to syringe
Amgen has disclosed a biosimilar Keytruda program • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products